Company Description
Anteris Technologies Global Corp., a structural heart company, discovers, develops, and commercializes medical devices to enhance the quality of life for patients with aortic stenosis.
Its lead product candidate is the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve.
The company also devlops ADAPT anti-calcification tissue, an anti-calcification preparation that transforms xenograft tissue into durable bioscaffolds that are used to mimic human tissue for surgical repair in multiple settings, including aortic valve replacement; and ComASUR delivery system, a physician-developed balloon expandable delivery system that contains a reinforced steerable catheter for a precise deflection through the heart anatomy in a controlled manner to avoid damage to the aorta.
Anteris Technologies Global Corp. was incorporated in 1999 and is based in Toowong, Australia.
| Country | Australia |
| Founded | 1999 |
| IPO Date | Dec 13, 2024 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 138 |
| CEO | Wayne Paterson |
Contact Details
Address: Toowong Tower, Level 3, Suite 302 Toowong, QLD 4066 Australia | |
| Phone | 61 13 0055 0310 |
| Website | anteristech.com |
Stock Details
| Ticker Symbol | AVR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $6.00 |
| CIK Code | 0002011514 |
| SIC Code | 3842 |
Key Executives
| Name | Position |
|---|---|
| Wayne Geoffrey Paterson | Chief Executive Officer, MD and Executive Director |
| Matthew McDonnell | Chief Financial Officer |
| David St. Denis | Chief Operating Officer |
| Stephen Anthony Denaro | Non-Executive Director and Company Secretary |
| Dr. Chris Meduri M.D., M.P.H. | Chief Medical Officer and Member of Medical Advisory Board |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 14, 2025 | SCHEDULE 13G | Filing |
| Feb 10, 2025 | SCHEDULE 13G | Filing |
| Jan 23, 2025 | SCHEDULE 13G | Filing |
| Jan 15, 2025 | 8-K | Current Report |
| Dec 19, 2024 | 8-K | Current Report |
| Dec 16, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Dec 16, 2024 | 8-K | Current Report |
| Dec 13, 2024 | 424B4 | Prospectus |
| Dec 13, 2024 | POS EX | Filing |
| Dec 12, 2024 | EFFECT | Notice of Effectiveness |